|
1
|
Lowrey PL and Takahashi JS: Genetics of
circadian rhythms in mammalian model organisms. Adv Genet.
74:175–230. 2011.PubMed/NCBI
|
|
2
|
Partch CL, Green CB and Takahashi JS:
Molecular architecture of the mammalian circadian clock. Trends
Cell Biol. 24:90–99. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Buhr ED and Takahashi JS: Molecular
components of the mammalian circadian clock. Kramer A and Merrow M:
circadian clocks, handbook of experimental pharmacology. 217:3–27.
2013. View Article : Google Scholar
|
|
4
|
Koike N, Yoo SH, Huang HC, Kumar V, Lee C,
Kim TK and Takahashi JS: Transcriptional architecture and chromatin
landscape of the core circadian clock in mammals. Science.
338:349–354. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Katada S and Sassone-Corsi P: The histone
methyltransferase MLL1 permits the oscillation of circadian gene
expression. Nat Struct Mol Biol. 17:1414–1421. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kettner NM, Katchy CA and Fu L: Circadian
gene variants in cancer. Ann Med. 46:208–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bechtold DA, Gibbs JE and Loudon AS:
Circadian dysfunction in disease. Trends Pharmacol Sci. 31:191–198.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kiessling S, Beaulieu-Laroche L, Blum ID,
Landgraf D, Welsh DK, Storch KF, Labrecque N and Cermakian N:
Enhancing circadian clock function in cancer cells inhibits tumor
growth. BMC Biol. 15:132017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cash E, Sephton SE, Chagpar AB, Spiegel D,
Rebholz WN, Zimmaro LA, Tillie JM and Dhabhar FS: Circadian
disruption and biomarkers of tumor progression in breast cancer
patients awaiting surgery. Brain Behav Immun. 48:102–114. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Greene MW: Circadian rhythms and tumor
growth. Cancer Lett. 318:115–123. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yasuniwa Y, Izumi H, Wang KY, Shimajiri S,
Sasaguri Y, Kawai K, Kasai H, Shimada T, Miyake K, Kashiwagi E, et
al: Circadian disruption accelerates tumor growth and
angio/stromagenesis through a Wnt signaling pathway. PLoS One.
5:e153302010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Dycke KC, Rodenburg W, van Oostrom CT,
VanKerkhof LW, Pennings JL, Roenneberg T, van Steeg H and
Vanderhorst GT: Chronically alternating light cycles increase
breast cancer risk in mice. Curr Biol. 25:1932–1937. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu L, Pelicano H, Liu J, Huang P and Lee
C: The circadian gene Period2 plays an important role in tumor
suppression and DNA damage response in vivo. Cell. 111:41–50. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Papagiannakopoulos T, Bauer MR, Davidson
SM, Heimann M, Subbaraj L, Bhutkar A, Bartlebaugh J, Vander Heiden
MG and Jacks T: Circadian rhythm disruption promotes lung
tumorigenesis. Cell Metab. 24:324–331. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gery S, Gombart AF, Yi WS, Koeffler C,
Hofmann WK and Koeffler HP: Transcription profiling of C/EBP
targets identifies Per2 as a gene implicated in myeloid leukemia.
Blood. 106:2827–2836. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gery S, Komatsu N, Baldjyan L, Yu A, Koo D
and Koeffler HP: The circadian gene per1 plays an important role in
cell growth and DNA damage control in human cancer cells. Mol Cell.
22:375–382. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang
C, Wang X, Wang Z, Cornelissen-Guillaume G and Halberg F: Circadian
gene mPer2 overexpression induces cancer cell apoptosis. Cancer
Sci. 97:589–596. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xiang S, Coffelt SB, Mao L, Yuan L, Cheng
Q and Hill SM: Period-2: A tumor suppressor gene in breast cancer.
J Circadian Rhythms. 6:42008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang X, Wood PA, Oh EY, Du-Quiton J,
Ansell CM and Hrushesky WJ: Down regulation of circadian clock gene
Period 2 accelerates breast cancer growth by altering its daily
growth rhythm. Breast Cancer Res Treat. 117:423–431. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Miyazaki K, Wakabayashi M, Hara Y and
Ishida N: Tumor growth suppression in vivo by overexpression of the
circadian component, PER2. Genes Cells. 15:351–358. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Oda A, Katayose Y, Yabuuchi S, Yamamoto K,
Mizuma M, Shirasou S, Onogawa T, Ohtsuka H, Yoshida H, Yoshida H,
et al: Clock gene mouse period2 overexpression inhibits growth of
human pancreatic cancer cells and has synergistic effect with
cisplatin. Anticancer Res. 29:1201–1210. 2009.PubMed/NCBI
|
|
22
|
Winter SL, Bosnoyan-Collins L, Pinnaduwage
D and Andrulis IL: Expression of the circadian clock genes Pert and
Per2 in sporadic and familial breast tumors. Neoplasia. 9:797–800.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ
and Chang JG: Deregulated expression of the PER1, PER2 and PER3
genes in breast cancers. Carcinogenesis. 26:1241–1246. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dai H, Zhang L, Cao M, Song F, Zheng H,
Zhu X, Wei Q, Zhang W and Chen K: The role of polymorphisms in
circadian pathway genes in breast tumorigenesis. Breast Cancer Res
Treat. 127:531–540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu
J and Koeffler HP: A role for the clock gene per1 in prostate
cancer. Cancer Res. 69:7619–7625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tokunaga H, Takebayashi Y, Utsunomiya H,
Akahira J, Higashimoto M, Mashiko M, Ito K, Niikura H, Takenoshita
S and Yaegashi N: Clinicopathological significance of circadian
rhythm-related gene expression levels in patients with epithelial
ovarian cancer. Acta Obstet Gynecol Scand. 87:1060–1070. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL,
Lin SF and Chang JG: Abnormal expression of period 1 (PER1) in
endometrial carcinoma. J Pathol. 206:111–120. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Relles D, Sendecki J, Chipitsyna G, Hyslop
T, Yeo CJ and Arafat HA: Circadian gene expression and
clinicopathologic correlates in pancreatic cancer. J Gastrointest
Surg. 17:443–450. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mazzoccoli G, Panza A, Valvano MR, Palumbo
O, Carella M, Pazienza V, Biscaglia G, Tavano F, Di Sebastiano P,
Andriulli A and Piepoli A: Clock gene expression levels and
relationship with clinical and pathological features in colorectal
cancer patients. Chronobiol Int. 28:841–851. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mostafaie N, Kallay E, Sauerzapf E, Bonner
E, Kriwanek S, Cross HS, Huber KR and Krugluger W: Correlated
downregulation of estrogen receptor beta and the circadian clock
gene Per1 in human colorectal cancer. Mol Carcinog. 48:642–647.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hu ML, Yeh KT, Lin PM, Hsu CM, Hsia HH,
Liu YC, Lin HY, Lin SF and Yang MY: Deregulated expression of
circadian clock genes in gastric cancer. BMC Gastroenterol.
14:672014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhao H, Zen ZL, Yang Y, Jin Y, Qiu MZ, Hu
XY, Han J, Liu KY, Liao JW, Xu RH and Zou QF: Prognostic relevance
of Period1 (Per1) and Period2 (Per2) expression in human gastric
cancer. Int J Clin Exp Pathol. 7:619–630. 2014.PubMed/NCBI
|
|
33
|
Lin YM, Chang JH, Yeh KT, Yang MY, Liu TC,
Lin SF, Su W and Chang JG: Disturbance of circadian gene expression
in hepatocellular carcinoma. Mol Carcinog. 47:925–933. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lengyel Z, Lovig C, Kommedal S, Keszthelyi
R, Szekeres G, Battyáni Z, Csernus V and Nagy AD: Altered
expression patterns of clock gene mRNAs and clock proteins in human
skin tumors. Tumor Biol. 34:811–819. 2013. View Article : Google Scholar
|
|
35
|
Gery S, Komatsu N, Kawamata N, Miller CW,
Desmond J, Virk RK, Marchevsky A, Mckenna R, Taguchi H and Koeffler
HP: Epigenetic silencing of the candidate tumor suppressor gene
Per1 in non-small cell lung cancer. Clin Cancer Res. 13:1399–1404.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yang MY, Yang WC, Lin PM, Hsu JF, Hsiao
HH, Liu YC, Tsai HJ, Chang CS and Lin SF: Altered expression of
circadian clock genes in human chronic myeloid leukemia. J Biol
Rhythms. 26:136–148. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hsu CM, Lin SF, Lu CT, Lin PM and Yang MY:
Altered expression of circadian clock genes in head and neck
squamous cell carcinoma. Tumor Biol. 33:149–155. 2012. View Article : Google Scholar
|
|
38
|
Thoennissen NH, Thoennissen GB, Abbassi S,
Nabavi-Nouis S, Sauer T, Doan NB, Gery S, Müller-Tidow C, Said JW
and Koeffler HP: Transcription factor CCAAT/enhancer-binding
protein alpha and critical circadian clock downstream target gene
PER2 are highly deregulated in diffuse large B-cell lymphoma. Leuk
Lymphoma. 53:1577–1585. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xia H, Niu Z, Ma H, Cao SZ, Hao SC, Liu ZT
and Wang F: Deregulated expression of the Per1 and Per2 in human
gliomas. Can J Neurol Sci. 37:365–370. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhanfeng N, Yanhui L, Zhou F, Shaocai H,
Guangxing L and Hechun X: Circadian genes Per1 and Per2 increase
radiosensitivity of glioma in vivo. Oncotarget. 6:9951–9958. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang MY, Chang JG, Lin PM, Tang KP, Chen
YH, Lin HY, Liu TC, Hsiao HH, Liu YC and Lin SF: Downregulation of
circadian clock genes in chronic myeloid leukemia: alternative
methylation pattern of hPER3. Cancer Sci. 97:1298–1307. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Etchegaray JP, Lee C, Wade PA and Reppert
SM: Rhythmic histone acetylation underlies transcription in the
mammalian circadian clock. Nature. 421:177–182. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ramakers C, Ruijter JM, Deprez RH and
Moorman AF: Assumption-free analysis of quantitative real-time
polymerase chain reaction (PCR) data. Neurosci Lett. 339:62–66.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Contreras-Leal E, Hernandez-Oliveras A,
Flores-Peredo L, Zarain-Herzberg A and Santiago-Garcia J: Histone
deacetylase inhibitors promote the expression of ATP2A3 gene in
breast cancer cell lines. Mol Carcinog. 55:1477–1485. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Khan A, Fornes O, Stigliani A, Gheorghe M,
Castro-Mondragon JA, van der Lee R, Bessy A, Chèneby J, Kulkarni
SR, Tan G, et al: JASPAR 2018: Update of the open-access database
of transcription factor binding profiles and its web framework.
Nucleic Acids Res. 46:D260–D266. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Amin MR, Dudeja PK, Ramaswamy K and
Malakooti J: Involvement of Sp1 and Sp3 in differential regulation
of human NHE3 promoter activity by sodium butyrate and
IFN-gamma/TNF-alpha. AJP Gastrointest Liver Physiol. 293:G374–G382.
2007. View Article : Google Scholar
|
|
48
|
Kiela PR, Kuscuoglu N, Midura AJ,
Midura-Kiela MT, Larmonier CB, Lipko M and Ghishan FK: Molecular
mechanism of rat NHE3 gene promoter regulation by sodium butyrate.
Am J Physiol Cell Physiol. 293:C64–C74. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Flores-Peredo L, Rodriguez G and
Zarain-Herzberg A: Induction of cell differentiation activates
transcription of the sarco/endoplasmic reticulum calcium-ATPase 3
gene (ATP2A3) in gastric and colon cancer cells. Mol Carcinog.
56:735–750. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Chirakkal H, Leech SH, Brookes KE, Prais
AL, Waby JS and Corfe BM: Upregulation of BAK by butyrate in the
colon is associated with increased Sp3 binding. Oncogene.
25:7192–7200. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu DC, Waby JS, Chirakkal H, Staton CA and
Corfe BM: Butyrate suppresses expression of neuropilin I in
colorectal cell lines through inhibition of Sp1 transactivation.
Mol Cancer. 9:2762010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Sarkar S, Abujamra AL, Loew JE, Forman LW,
Perrine SP and Faller DV.: Histone deacetylase inhibitors reverse
CpG methylation by regulating DNMT1 through ERK signaling.
Anticancer Res. 3:2723–2732. 2011.
|
|
53
|
Shin H, Kim JH, Lee YS and Lee YC: Change
in gene expression profiles of secreted frizzled-related proteins
(SFRPs) by sodium butyrate in gastric cancers: Induction of
promoter demethylation and histone modification causing inhibition
of Wnt signaling. Int J Oncol. 40:1533–1542. 2012.PubMed/NCBI
|
|
54
|
Masri S and Sassone-Corsi P: Plasticity
and specificity of the circadian epigenome. Nat Neurosci.
13:1324–1329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Meng CF, Zhu XJ, Peng G and Dai DQ:
Promoter histone H3 lysine 9 di-methylation is associated with DNA
methylation and aberrant expression of p16 in gastric cancer cells.
Oncol Rep. 22:1221–1227. 2009.PubMed/NCBI
|
|
56
|
Chen MY, Liao WS, Lu Z, Bornmann WG,
Hennessey V, Washington MN, Rosner GL, Yu Y, Ahmed AA and Bast RC
Jr: Decitabine and suberoylanilide hydroxamic acid (saha) inhibit
growth of ovarian cancer cell lines and xenografts while inducing
expression of imprinted tumor suppressor genes, apoptosis, G2/M
arrest and autophagy. Cancer. 117:4424–4438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Vibhakar R, Foltz G, Yoon JG, Field L, Lee
H, Ryu GY, Pierson J, Davidson B and Madan A: Dickkopf-1 is an
epigenetically silenced candidate tumor suppressor gene in
medulloblastoma. Neuro Oncol. 9:135–144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Chang J, Varghese DS, Gillam MC, Peyton M,
Modi B, Schiltz RL, Girard L and Martinez ED: Differential response
of cancer cells to HDAC inhibitors trichostatin A and depsipeptide.
Br J Cancer. 106:116–125. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hublitz P, Albert M and Peters AH:
Mechanisms of transcriptional repression by histone lysine
methylation. Int J Dev Biol. 53:335–354. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Varier RA and MarcTimmers HT: Histone
lysine methylation and demethylation pathways in cancer. Biochim
Biophys Acta. 1815:75–89. 2011.PubMed/NCBI
|
|
61
|
Curtis AM, Seo SB, Westgate EJ, Rudic RD,
Smyth EM, Chakravarti D, Fitzgerald GA and McNamara P: Histone
acetyltransferase-dependent chromatin remodeling and the vascular
clock. J Biol Chem. 279:7091–7097. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Etchegaray JP, Yang X, DeBruyne JP, Peters
AH, Weaver DR, Jenuwein T and Reppert SM: The polycomb group
protein EZH2 is required for mammalian circadian clock function. J
Biol Chem. 281:21209–21215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Law AY, Yeung BH, Ching LY and Wong CK:
Sp1 is a transcriptional repressor to stanniocalcin-1 expression in
TSA-treated human colon cancer cells, HT29. J Cell Biochem.
112:2089–2096. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Gartel AL, Ye X, Goufman E, Shianov P, Hay
N, Najmabandi F and Tyner AL: Myc repress the p21(WAF1/CIP1)
promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci USA.
98:4510–4515. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Doetzlhofer A, Rotheneder H, Lagger G,
Koranda M, Kurtev V, Brosch G, Wintersberger E and Seiser C:
Histone deacetylase 1 can repress transcription by binding to Sp1.
Mol Cell Biol. 19:5504–5511. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Hida A, Koike N, Hirose M, Hattori M,
Sakaki Y and Tei H: The human and mouse Period1 genes: five
well-conserved E-boxes additively contribute to the enhancement of
mPer1 transcription. Genomics. 65:224–233. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Taruscio D, Zoraqi GK, Falchi M, Iosi F,
Paradisi S, DiFiore B, Lavia P and Falbo V: The human Per1 gene:
Genomic organization and promoter analysis of the first human
orthologue of the Drosophila period gene. Gene. 253:161–170. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Koyanagi S, Hamdan AM, Horiguchi M,
Kusunose N, Okamoto A, Matsunaga N and Ohdo S: cAMP-response
element (CRE)-mediated transcription by activating transcription
factor-4 (ATF4) is essential for circadian expression of the
Period2 gene. J Biol Chem. 286:32416–32423. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Doi M, Hirayama J and Sassone-Corsi P:
Circadian regulator CLOCK is a histone acetyltransferase. Cell.
125:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Grimaldi B, Nakahata Y, Sahar S, Kaluzova
M, Gauthier D, Pham K, Patel N, Hirayama J and Sassone-Corsi P:
Chromatin remodeling and circadian control: Master regulator CLOCK
is an enzyme. Cold Spring Harb Symp Quant Biol. 72:105–112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
